Results 61 to 70 of about 20,614 (289)
CNS Neuroscience & Therapeutics, 2023 Aim Sacubitril/valsartan is a new cardiovascular agent characterized by its dual inhibition on the reninangiotensin system (RAS) and the neprilysin. As neprilysin also involved itself in the degradation of amyloid‐β, there is an ongoing concern about the
Congqin Chen +3 more
semanticscholar +1 more source
Principles of focused ultrasound [PDF]
, 2018 Focused ultrasound (FUS/HIFU) relies on ablation of pathological tissues, by delivering sufficiently high level of acoustic energy in situ of the human body. Magnetic Resonance guided FUS (MRgFUS/HIFU) and Ultrasound guided (USgFUS/HIFU) are image guided
Melzer, Andreas, Mihcin, Senay
core +2 more sources
Single therapeutic and supratherapeutic doses of sacubitril/valsartan (LCZ696) do not affect cardiac repolarization [PDF]
, 2016 Purpose: Sacubitril/valsartan (LCZ696) is a first-in-class angiotensin receptor neprilysin inhibitor (ARNI) indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA class II ...
Iris Rajman +7 more
core +1 more source
JAMA cardiology, 2021 Importance The use of sacubitril/valsartan is not endorsed by practice guidelines for use in patients with New York Heart Association class IV heart failure with a reduced ejection fraction because of limited clinical experience in this population ...
D. Mann +17 more
semanticscholar +1 more source
From ARB to ARNI in Cardiovascular Control [PDF]
, 2016 Coexistence of hypertension, diabetes mellitus and chronic kidney disease synergistically aggravates the risk of cardiovascular and renal morbidity and mortality.
Danser, A.H.J. (Jan) +3 more
core +1 more source
Melhora no Consumo Máximo de Oxigênio e na Ventilação após Tratamento com Sacubitril-Valsartana [PDF]
Arquivos Brasileiros de Cardiologia, 2020 Resumo Fundamento O tratamento com sacubitril-valsartana teve seu benefício prognóstico confirmado no ensaio PARADIGM-HF. No entanto, dados sobre alterações no teste de esforço cardiopulmonar (TECP) com o uso de sacubitril-valsartana são escassos ...
António Valentim Gonçalves +10 more
doaj +3 more sources
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure Management.
JAMA cardiology, 2023 Importance The US Food and Drug Administration expanded labeling of sacubitril-valsartan from the treatment of patients with chronic heart failure (HF) with reduced ejection fraction (EF) to all patients with HF, noting the greatest benefits in those ...
A. Bhatt +11 more
semanticscholar +1 more source
Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu +3 more
wiley +1 more source
Sakubitriili ja valsartaani kombinatsioon südamepuudulikkuse ravis Eestis [PDF]
, 2018 Eesti Arst 2018; 97(2):95 ...
Irs, Alar
core +2 more sources
Frontiers in Cardiovascular Medicine, 2023 Background Diffuse interstitial myocardial fibrosis is a key common pathological manifestation in hypertensive heart disease (HHD) progressing to heart failure (HF).
V. Lee +11 more
semanticscholar +1 more source